Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

Equity Bottom-Up

<ul>
<li>TransMedics, a medical technology company and multi-organ technology platform provider with a dedicated fleet of modern jets, has a clear leadership position in a ~$8B TAM.</li>
<li>Their Organ Care System (OCS) has already been used for over 3,000 human organ transplants, including liver, heart and lung.  </li>
<li>I view valuation (~5x ‘25E revenues) as attractive and current price levels offer a great entry point, with major catalysts coming up in 2025.</li>
</ul>


TransMedics, a medical technology company and multi-organ technology platform provider with a dedicated fleet of modern jets, has a clear leadership position in a ~$8B TAM.
Their Organ Care System (OCS) has already been used for over 3,000 human organ transplants, including liver, heart and lung.  
I view valuation (~5x ‘25E revenues) as attractive and current price levels offer a great entry point, with major catalysts coming up in 2025.


2025 High Conviction: TransMedics, The Market Leader and Disruptor In Organ Transplant Therapy

<ul>
<li>TransMedics Group stock surged ~20% on blowout 1Q’25 earnings on Friday after the company beat earnings expectations and hiked 2025 revenue guidance.</li>
<li>I launched coverage of the stock in November 2024 and added TransMedics Group to my high conviction list of ideas.</li>
<li>TransMedics Group shares have massively outperformed in 2025 with shares up ~79% over the year. I acknowledge limited upside and lower my PT to $118 on peer-group multiple compression.</li>
</ul>


TransMedics Group stock surged ~20% on blowout 1Q’25 earnings on Friday after the company beat earnings expectations and hiked 2025 revenue guidance.
I launched coverage of the stock in November 2024 and added TransMedics Group to my high conviction list of ideas.
TransMedics Group shares have massively outperformed in 2025 with shares up ~79% over the year. I acknowledge limited upside and lower my PT to $118 on peer-group multiple compression.


2025 High Conviction Update: TransMedics, Cut Long Exposure and Move To the Sidelines

External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

<ul><li>TMDX is a high-growth med-tech company specializing in organ transplant therapy</li><li>Despite expensive traditional valuation metrics, TMDX offers a compelling investment opportunity</li><li>Company recently became GAAP profitable and free cash flow positive, indicating a bright future ahead</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

TMDX is a high-growth med-tech company specializing in organ transplant therapyDespite expensive traditional valuation metrics, TMDX offers a compelling investment opportunityCompany recently became GAAP profitable and free cash flow positive, indicating a bright future aheadThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Transmedics Group Inc (TMDX) - Thursday, Oct 24, 2024

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

<ul>
<li>The potential/market size of GLP-1 drugs is much greater-than-expected. Indication expansion could easily generate big returns. Investment strategy for GLP-1 drugs should be long-term, which is expected to bring alpha.</li>
<li>Supply-Demand relationship of entire market would change due to popularization of GLP-1 drugs.This is not only for healthcare, but also cause a change in the investment logic of other industries.</li>
<li>It’s recommended to re-examine stock positions in portfolio. Because each indication expansion of GLP-1 drugs would mean a decrease in demand in another field, leading to potential stock price plummet.</li>
</ul>


The potential/market size of GLP-1 drugs is much greater-than-expected. Indication expansion could easily generate big returns. Investment strategy for GLP-1 drugs should be long-term, which is expected to bring alpha.
Supply-Demand relationship of entire market would change due to popularization of GLP-1 drugs.This is not only for healthcare, but also cause a change in the investment logic of other industries.
It’s recommended to re-examine stock positions in portfolio. Because each indication expansion of GLP-1 drugs would mean a decrease in demand in another field, leading to potential stock price plummet.


GLP-1 Drugs – Are They Dessert or Time Bomb to Your Portfolio?

United States

TransMedics Group, Inc. operates as a biotechnology company. The Company offers transplant therapy for end-stage organ failure patients across multiple disease states. TransMedics Group serves patients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

TransMedics Group (TMDX US)

2025 High Conviction: TransMedics, The Market Leader and Disruptor In Organ Transplant Therapy

TransMedics, the world's leader in transforming organ transplant therapy, is my high-risk/high-reward 2025 conviction idea in healthcare sector.

Andrei Zakharov

2025 High Conviction Update: TransMedics, Cut Long Exposure and Move To the Sidelines

TransMedics, a US-based multi-organ technology platform, delivered sizable “beat and raise” in 1Q’25. I launched coverage of the stock in November...

Andrei Zakharov

Transmedics Group Inc (TMDX) - Thursday, Oct 24, 2024

TMDX is a high-growth med-tech company specializing in organ transplant therapy. Despite expensive traditional valuation metrics, TMDX offers a...

Value Investors Club (VIC)

GLP-1 Drugs – Are They Dessert or Time Bomb to Your Portfolio?

GLP-1s will be the next major opportunity in healthcare, which won't be limited to weight loss drugs. But when they expand new indications,...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)